aTyr Investors Face Dec. 8 Lead‑Plaintiff Deadline as Firms Press Securities Case
The suits stem from a September disclosure that the Phase 3 EFZO‑FIT study missed its steroid‑reduction goal, sending shares down roughly 83%.
Overview
- Hagens Berman, the Law Offices of Howard G. Smith, Levi & Korsinsky, and Rosen Law Firm are urging shareholders to move for lead‑plaintiff status by Monday’s deadline.
- Complaints assert aTyr overstated efzofitimod’s efficacy and its ability to enable complete steroid tapering and concealed adverse facts about the EFZO‑FIT trial design.
- Most notices cite a proposed class period of November 7, 2024 through September 12, 2025, while Rosen lists January 16, 2025 through September 12, 2025.
- The litigation follows a September 15 announcement that EFZO‑FIT failed its primary endpoint measuring change in mean daily oral corticosteroid dose at week 48, after which the stock fell from $6.03 to $1.02.
- No class has been certified and the cases are in early stages, and aTyr has said it will consult the FDA on possible next steps.